Mirae Asset Report Shows Korean Pharma & Bio Firms Strengthening Fundamentals Amid Market Weakness

Domestic expectations for the Korean pharmaceutical and biotechnology industry have risen. While external factors such as interest rates and supply‑demand dynamics have kept pharma and bio stocks relatively weak, industry activity shows a different picture. Large‑scale mergers and acquisitions, technology exports, expansion of global market share, and investments in production capacity are occurring across the sector, leading analysts to view corporate fundamentals as strengthening. According to a report released on the 7th by Mirae Asset Securities, major domestic pharma and bio companies are enhancing global competitiveness through various strategies. The report acknowledges that interest rates, exchange rates and supply conditions may affect short‑term stock discount rates, but emphasizes the positive impact of large‑scale technology exports and other growth initiatives.